On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious RSV LRTI, according to new research.
On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious RSV LRTI, according to research published at the ATS 2024 International Conference.
Pediatric Impact of COVID-19 and Other Respiratory Infections Clinical Prediction Tool for Prioritizing Respiratory Syncytial Virus Prevention Products for
On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious RSV LRTI, according to research published at the ATS 2024 International Conference.